RK

Rubi Kumari

Active Director Director DIN 08766475
DIN 08766475 First appointment Jun 2020 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jun 2020
Shareholding value •••• Premium profile

About Rubi Kumari

Data last updated:

Rubi Kumari is a Director at Teliqon Pharmaceutical Private Limited (since 2020). The company operates in Pharma. Teliqon Pharmaceutical Private Limited reported revenue of ₹5.2 Lakh (FY 2025).

DIN 08766475
Primary Designation Director
Industry Pharma
First Appointment 18 Jun 2020
Oldest Company Age 6 yrs
Largest company Teliqon Pharmaceutical Private Limited · ₹5.2 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director18 Jun 20202020₹5.2 Lakh (FY 2025)Active

Board colleagues of Rubi Kumari

NameDINCompanyDesignation
Ram Nivas Mishra08766474Teliqon Pharmaceutical Private LimitedDirector

Directorship timeline

Open interactive timeline →
Teliqon Pharmaceutical Private Limited
Premium access

Shareholding and investment profile for Rubi Kumari

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rubi Kumari

Rubi Kumari currently holds 1 directorship: Teliqon Pharmaceutical Private Limited (Director, since 18 Jun 2020, revenue ₹5.2 Lakh (FY 2025)).

Rubi Kumari was first appointed on 18 Jun 2020 as Director at Teliqon Pharmaceutical Private Limited.

The current boards of Rubi Kumari's companies include Ram Nivas Mishra (Teliqon Pharmaceutical Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available